Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Austin Health
With
Ballarat Health Services
Queen Elizabeth Hospital, Adelaide
Royal North Shore Hospital
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age\>18 years
Histological diagnosis of colorectal cancer
Metastatic disease not amenable to resection
Measurable disease as assessed by CT scan using RECIST criteria
Received and failed fluoropyrimidine therapy, where failure is defined as radiological progression after therapy for metastatic disease, prior adjuvant therapy, or toxicity limiting further therapy
Received and failed oxaliplatin therapy, where failure is defined as radiological progression after therapy for metastatic disease, prior adjuvant therapy ,or toxicity (including neuro-toxicity) limiting further therapy
Received and failed irinotecan therapy, where failure is defined as radiological progression after therapy for metastatic disease or toxicity limiting further therapy
ECOG PS 0-1
Adequate bone marrow function with platelets \> 100 X 109/l; neutrophils \> 1.5 X 109/l
Adequate renal function, with calculated creatinine clearance \>40 ml/min (Cockcroft and Gault).
Adequate hepatic function with serum total bilirubin \< 1.25 X upper limit of normal range and ALT or AST\<2.5xULN (\<5xULN if liver metastases present)
Life expectancy of at least 12 weeks
No other concurrent uncontrolled medical conditions
No other malignant disease apart from non-melanotic skin cancer or carcinoma in situ of the uterine cervix or any other cancer treated with curative intent \>2 years previously without evidence of relapse
Women and partners of women of childbearing potential must agree to use adequate contraception
Written informed consent including consent for biomarker studies
You may not be if
Medical or psychiatric conditions that compromise the patient's ability to give informed consent or to complete the protocol
Prior treatment with drugs targeting EGFR such as cetuximab, panitumumab or erlotinib
Participation in any investigational drug study within the previous 4 weeks
Patients with uncontrolled clinically significant cardiac disease, arrhythmias or angina pectoris
